Icosapent ethyl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 592879

CAS#: 86227-47-6

Description: Icosapent ethyl is used for the treatment of hypertriglyceridemia.

Chemical Structure

Icosapent ethyl
CAS# 86227-47-6

Theoretical Analysis

MedKoo Cat#: 592879
Name: Icosapent ethyl
CAS#: 86227-47-6
Chemical Formula: C22H34O2
Exact Mass: 330.2559
Molecular Weight: 330.512
Elemental Analysis: C, 79.95; H, 10.37; O, 9.68

Price and Availability

Size Price Availability Quantity
5.0mg USD 250.0 2 Weeks
50.0mg USD 390.0 2 Weeks
Bulk inquiry

Synonym: Icosapent ethyl;

IUPAC/Chemical Name: 5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)-


InChi Code: InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 330.512 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Braeckman RA, Stirtan WG, Soni PN. Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects. Clin Pharmacol Drug Dev. 2015 Mar;4(2):143-148. Epub 2014 Dec 3. PubMed PMID: 26097794; PubMed Central PMCID: PMC4467261.

2: Kim ES, McCormack PL. Icosapent ethyl: a review of its use in severe hypertriglyceridemia. Am J Cardiovasc Drugs. 2014 Dec;14(6):471-8. doi: 10.1007/s40256-014-0099-7. Review. PubMed PMID: 25428605.

3: Ballantyne CM, Bays HE, Philip S, Doyle RT Jr, Braeckman RA, Stirtan WG, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies. Atherosclerosis. 2016 Oct;253:81-87. doi: 10.1016/j.atherosclerosis.2016.08.005. Epub 2016 Aug 20. PubMed PMID: 27596132.

4: Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015 Jan;35(1):45-51. doi: 10.1007/s40261-014-0252-8. PubMed PMID: 25471740; PubMed Central PMCID: PMC4281350.

5: Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016 May-Jun;10(3):635-645.e1. doi: 10.1016/j.jacl.2016.02.008. Epub 2016 Feb 23. PubMed PMID: 27206952.

6: Kedia AW, Lynch E. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Postgrad Med. 2015;127(8):869-73. doi: 10.1080/00325481.2015.1100086. Epub 2015 Oct 9. PubMed PMID: 26453247.

7: Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Doyle RT Jr, Philip S, Soni PN, Juliano RA. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug;13(6):239-47. doi: 10.1089/met.2014.0137. Epub 2015 Apr 20. PubMed PMID: 25893544.

8: Nelson SD, Munger MA. Icosapent ethyl for treatment of elevated triglyceride levels. Ann Pharmacother. 2013 Nov;47(11):1517-23. doi: 10.1177/1060028013504079. Epub 2013 Nov 5. Review. PubMed PMID: 24259598.

9: Fares H, Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV. Icosapent ethyl for the treatment of severe hypertriglyceridemia. Ther Clin Risk Manag. 2014 Jun 24;10:485-92. doi: 10.2147/TCRM.S36983. eCollection 2014. Review. PubMed PMID: 25028554; PubMed Central PMCID: PMC4077874.

10: Bays HE, Ballantyne CM, Doyle RT Jr, Juliano RA, Philip S. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016 Sep;125:57-64. doi: 10.1016/j.prostaglandins.2016.07.007. Epub 2016 Jul 11. PubMed PMID: 27418543.

11: Ballantyne CM, Braeckman RA, Soni PN. Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opin Pharmacother. 2013 Jul;14(10):1409-16. doi: 10.1517/14656566.2013.798645. Epub 2013 May 24. PubMed PMID: 23701295.

12: Castaldo RS. A retrospective case series of the lipid effects of switching from omega-3 fatty acid ethyl esters to icosapent ethyl in hyperlipidemic patients. Postgrad Med. 2014 May;126(3):268-73. doi: 10.3810/pgm.2014.05.2775. PubMed PMID: 24977343.

13: Bays HE, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am J Cardiovasc Drugs. 2013 Feb;13(1):37-46. doi: 10.1007/s40256-012-0002-3. PubMed PMID: 23325450; PubMed Central PMCID: PMC3572383.

14: Castaldo RS. Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series. Drugs Ther Perspect. 2016;32:162-169. Epub 2016 Mar 8. PubMed PMID: 27065746; PubMed Central PMCID: PMC4801984.

15: Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). J Clin Lipidol. 2015 May-Jun;9(3):377-83. doi: 10.1016/j.jacl.2014.11.009. Epub 2014 Nov 29. PubMed PMID: 26073397.

16: Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study). Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005. Epub 2013 Aug 1. PubMed PMID: 23992935.

17: Reddy KJ, Chowdhury S. Improving lipids with prescription icosapent ethyl after previous use of fish oil dietary supplements. Future Cardiol. 2016 May;12(3):261-8. doi: 10.2217/fca-2015-0009. Epub 2016 Apr 12. PubMed PMID: 27070379.

18: Hassan A, Tajuddin N, Shaikh A. Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl. Cardiol Ther. 2015 Jun;4(1):83-93. doi: 10.1007/s40119-014-0032-9. Epub 2014 Dec 17. PubMed PMID: 25515964; PubMed Central PMCID: PMC4472650.

19: Braeckman RA, Stirtan WG, Soni PN. Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adults. Drugs R D. 2014 Sep;14(3):159-64. doi: 10.1007/s40268-014-0053-9. PubMed PMID: 24973042; PubMed Central PMCID: PMC4153963.

20: Braeckman RA, Stirtan WG, Soni PN. Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22. PubMed PMID: 26097787; PubMed Central PMCID: PMC4467252.